Northern Trust’s ADC Therapeutics ADCT Stock Holding History

Northern Trust’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$636K	Buy	594,025 +41,824	+8%	+$122K	﹤0.01%	3605
2026 Q1	$2.07M	Buy	552,201 +114,650	+26%	+$452K	﹤0.01%	2961
2025 Q4	$1.54M	Buy	437,551 +19,984	+5%	+$81.1K	﹤0.01%	3142
2025 Q3	$1.67M	Sell	417,567 -9,319	-2%	-$29.4K	﹤0.01%	3130
2025 Q2	$1.14M	Sell	426,886 -69,258	-14%	-$146K	﹤0.01%	3310
2025 Q1	$700K	Buy	496,144 +19,951	+4%	+$33.9K	﹤0.01%	3428
2024 Q4	$948K	Sell	476,193 -4,844	-1%	-$12.7K	﹤0.01%	3418
2024 Q3	$1.52M	Buy	481,037 +458,023	+1,990%	+$1.44M	﹤0.01%	3157
2024 Q2	$72.7K	Buy	+23,014	New	+$91.5K	﹤0.01%	4125

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust's ADCT Position: Q2 2026 in Review

Northern Trust increased its ADC Therapeutics (ADCT) stake by 7.6% in Q2 2026, buying an estimated $122K and bringing the position to 594,025 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #3605.

Northern Trust first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.07M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Northern Trust held 594,025 shares of ADC Therapeutics worth $636K as of Q2 2026.
Northern Trust bought 41,824 ADC Therapeutics shares in Q2 2026, an estimated $122K.
ADC Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3605 holding.
Northern Trust first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
Northern Trust's ADC Therapeutics position peaked at $2.07M in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.